In our weekly expert view piece, Dr Alan Marks, chairman of the Alliance for Patient Access examines challenges faced by cancer patients in accessing precision 5 July 2016
In our weekly expert view piece, Elisabethann Wright, partner at international law firm Hogan Lovells, outlines some of the potential risks if British voters op 21 June 2016
In our weekly expert view piece Saoirse Fitzpatrick, advocacy officer at British health charity StopAids responds to claims made by AstraZeneca chief executive 17 June 2016
In our weekly expert view piece, chief executive of the BioIndustry Association (BIA), Steve Bates, explains why he thinks it is vital the UK remains a part of 14 June 2016
Sander van Deventer, Managing Partner of Forbion Capital Partners, analyses the challenges facing European start-ups and asks what could be done to improve the 7 June 2016
In our weekly expert view piece, Ed Corbett, engagement manager at specialist pharmaceutical strategy consultants, Novasecta, examines the British biotech lands 24 May 2016
In our weekly expert view piece Dr Nick Meyers, programme director at Boyd Consultants examines the implications what the regulatory and legislative landscape i 10 May 2016
In our weekly expert view piece Ed Corbett, engagement manager at Novosecta, questions whether UK pharma giant GlaxoSmithKline has the right strategy in place t 3 May 2016
In our weekly expert view piece, Robert Finkel, CEO and lead strategist at Freshblood Health Market Consultants, takes a look at the concept of 'branded science 25 April 2016
In our weekly expert view piece, Pam Taak, senior associate in the Life Sciences & Healthcare practice of Norton Rose Fulbright LLP, examines the implications o 22 March 2016
In our weekly expert view piece, John Kokai-Kun, PhD, vice-president of non-clinical affairs at Synthetic Biologics, examines a new way to extend the life and u 12 February 2016
In our weekly expert view piece, John Maloney, commerical product director at Bloomberg BNA and editors of Bloomberg law: corporate transactions, examines the S 9 February 2016
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.